MediWoundNASDAQ: MDWD

Approval Helps Solidify NexoBrid's Position in the U.S. as a Safe and Effective Non-Surgical Burn Treatment for All Ages Approval Helps Solidify NexoBrid's Position in the U.S. as a Safe and Effective Non-Surgical Burn Treatment for All Ages

MediWound Ltd. (NASDAQ:MDWD ) Q2 2024 Earnings Conference Call August 14, 2024 8:30 AM ET Company Participants Gaia Shamis - IR, LifeSci Advisors Ofer Gonen - Chief Executive Officer Hani Luxenburg - Chief Financial Officer Barry Wolfenson - EVP of Strategy & Corporate Development Conference Call Participants Joshua Jennings - TD Cowen Swayampakula Ramakanth - HC Wainwright Michael Okunewitch - Maxim Group Operator Good day and welcome to MediWound's Second Quarter 2024 Earnings Call.

MediWound (MDWD) came out with a quarterly loss of $0.68 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to earnings of $0.10 per share a year ago.

MediWound (MDWD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NEXT Confirms NexoBrid's Proven Safety and Efficacy in Eschar Removal, Significantly Reducing Surgical Procedures for Burn Patients NEXT Confirms NexoBrid's Proven Safety and Efficacy in Eschar Removal, Significantly Reducing Surgical Procedures for Burn Patients

Research Published in THE LANCET's eClinicalMedicine EscharEx ® Outperforms Non-Surgical Standard of Care in Debridement and Promotion of Healthy Granulation Tissue

Funds to be used for clinical development of EscharEx ® to treat diabetic foot ulcers (DFUs)

GOTHENBURG, Sweden , July 15, 2024 /PRNewswire/ -- Mölnlycke Health Care, a world-leading MedTech company specialising in solutions for wound care and surgical procedures, announced today an investment of US $15m in MediWound Ltd. (Nasdaq: MDWD) (MediWound) through a definitive share purchase agreement in a private investment in public equity (PIPE).

MediWound Ltd. (NASDAQ:MDWD ) Q1 2024 Earnings Conference Call May 29, 2024 8:30 AM ET Company Participants Ofer Gonen - Chief Executive Officer Hani Luxenburg - Chief Financial Officer Barry Wolfenson - Executive Vice President of Strategy, Corporate Development Daniel Ferry - Managing Director, LifeSci Advisors Conference Call Participants Josh Jennings - TD Cowen Francois Brisebois - Oppenheimer Swayampakula Ramakanth - HC Wainwright Michael Okunewitch - Maxim Group Operator Good day!